JHVS is hosted by the Ministry of Health, Labour and Welfare, and BioJapan 2025, Regenerative Medicine JAPAN 2025, healthTECH, and JAPAN 2025 will also be held on the same three days.

Our company has been developing antibodies established by the Immunodiagnostics Group at Juntendo University as therapeutic agents for malignant tumors.
Our unique discovery platform allows us to obtain antibodies that bind to the surface of cancer cells and directly cause cell death without causing damage to the normal cells.

We are currently conducting research and development of therapeutic agents, diagnostic agents, and ADCs (Antibody Drug Conjugates) for malignant lymphoma, mesothelioma, pancreatic cancer, invasive lobular carcinoma (breast cancer), and other cancers.

At this exhibition, we aim to find partners to advance clinical development. Please stop by and looking forward to introducing all of you.